E
Erik W.A. Marijt
Researcher at Leiden University Medical Center
Publications - 54
Citations - 1923
Erik W.A. Marijt is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 21, co-authored 52 publications receiving 1669 citations. Previous affiliations of Erik W.A. Marijt include Leiden University.
Papers
More filters
Journal ArticleDOI
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial
J.M. van Laar,Dominique Farge,Jacob K. Sont,Kamran Naraghi,Zora Marjanovic,Jérôme Larghero,Annemie J. Schuerwegh,Erik W.A. Marijt,Madelon C. Vonk,Anton Schattenberg,Marco Matucci-Cerinic,A E Voskuyl,A.A. van de Loosdrecht,Thomas Daikeler,Ina Kötter,Marc Schmalzing,Thierry Martin,Bruno Lioure,S.M. Weiner,Alexander Kreuter,Christophe Deligny,Jean-Marc Durand,Paul Emery,Klaus P Machold,F. Sarrot-Reynauld,Klaus Warnatz,Daniel Adoue,Joël Constans,Hans-Peter Tony,N. Del Papa,A Fassas,Andrea Himsel,David Launay,A. Lo Monaco,P. Philippe,Isabelle Quéré,E. Rich,Rene Westhovens,Bridget Griffiths,Riccardo Saccardi,F.H.J. van den Hoogen,Willem E. Fibbe,Gérard Socié,Alois Gratwohl,Alan Tyndall +44 more
TL;DR: Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased treatment-related mortality in the first year after treatment, however, HCST conferred a significant long-term event-free survival benefit.
Journal ArticleDOI
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
Roelof Willemze,Stefan Suciu,Giovanna Meloni,Boris Labar,Jean Pierre Marie,Constantijn J. M. Halkes,Petra Muus,Martin Mistrik,Sergio Amadori,Giorgina Specchia,Francesco Fabbiano,Francesco Nobile,Marco Sborgia,Andrea Camera,Dominik Selleslag,François Lefrère,Domenico Magro,Simona Sica,Nicola Cantore,Meral Beksac,Zwi N. Berneman,Xavier Thomas,Lorella Melillo,Jose E. Guimaraes,Pietro Leoni,Mario Luppi,Maria Enza Mitra,Dominique Bron,Georges Fillet,Erik W.A. Marijt,Adriano Venditti,Anne Hagemeijer,Marco Mancini,Joop H. Jansen,Daniela Cilloni,Liv Meert,Paola Fazi,Marco Vignetti,Silvia Maria Trisolini,Franco Mandelli,Theo de Witte +40 more
TL;DR: Patients of all ages with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tandem duplication) mutation, or with secondary AML benefitted from HD cytarabine, especially in patients younger than age 46 years.
Journal ArticleDOI
Minor histocompatibility antigens in human stem cell transplantation
TL;DR: Characterization of clinical immune responses in patients treated for relapsed leukemia after allogeneic SCT with donor lymphocyte infusion in the absence of GVHD may lead to the characterization of new mHags that can be exploited to generate tumor-specific immune responses.
Journal ArticleDOI
HLA class II upregulation during viral infection leads to HLA-DP–directed graft-versus-host disease after CD4+ donor lymphocyte infusion
Sanja Stevanović,Cornelis A.M. van Bergen,Simone A.P. van Luxemburg-Heijs,Boris van der Zouwen,Ekaterina S. Jordanova,Alwine B. Kruisselbrink,Marian van de Meent,Jessica C. Harskamp,Frans H.J. Claas,Erik W.A. Marijt,Jaap Jan Zwaginga,Constantijn J.M. Halkes,Inge Jedema,Marieke Griffioen,J.H. Frederik Falkenburg +14 more
TL;DR: The data demonstrate that GVHD after HLA-DPB1-mismatched CD4+ DLI can be mediated by allo-reactive Hla-DPb1-directed CD4- T cells and that ongoing viral infections inducing HLA class II expression on nonhematopoietic cells may increase the likelihood of GV HD development.
Journal ArticleDOI
Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
Renee M.Y. Barge,C. W. J. Starrenburg,Jhf Falkenburg,Willem E. Fibbe,Erik W.A. Marijt,Roelof Willemze +5 more
TL;DR: The use of Campath in vivo was associated with a significant reduction in GVHD but at the cost of impaired immune reconstitution, and successful pre-emptive antiviral therapy resulted in low TRM of 8%.